Addex Therapeutics Ltd

10.80-0.4500-4.00%Vol 7.40K1Y Perf 48.35%
Jun 14th, 2021 15:10 DELAYED
BID10.80 ASK11.10
Open10.80 Previous Close11.25
Pre-Market- After-Market-
 - -  - -%
Target Price
28.00 
Analyst Rating
— — 0.00
Potential %
159.26 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     53.19
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap88.69M 
Earnings Rating
Price Range Ratio 52W %
12.45 
Earnings Date
19th May 2021

Today's Price Range

10.4310.98

52W Range

7.0037.52

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
3.95%
1 Month
11.92%
3 Months
-1.01%
6 Months
-14.29%
1 Year
48.35%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ADXN10.80-0.4500-4.00
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.65-0.5318.46
Q03 2020--0.78-
Q02 2020--0.75-
Q01 2020--0.99-
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.65
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume7.40K
Shares Outstanding8.21M
Trades Count75
Dollar Volume145.83K
Avg. Volume62.62K
Avg. Weekly Volume10.53K
Avg. Monthly Volume5.20K
Avg. Quarterly Volume7.36K

Addex Therapeutics Ltd (NASDAQ: ADXN) stock closed at 10.8 per share at the end of the most recent trading day (a -4% change compared to the prior day closing price) with a volume of 7.40K shares and market capitalization of 88.69M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 27 people. Addex Therapeutics Ltd CEO is Tim Dyer.

The one-year performance of Addex Therapeutics Ltd stock is 48.35%, while year-to-date (YTD) performance is -19.4%. ADXN stock has a five-year performance of %. Its 52-week range is between 7 and 37.52, which gives ADXN stock a 52-week price range ratio of 12.45%

Addex Therapeutics Ltd currently has a PE ratio of -4.20, a price-to-book (PB) ratio of 3.54, a price-to-sale (PS) ratio of 19.85, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.15%, a ROC of -53.88% and a ROE of -52.69%. The company’s profit margin is -%, its EBITDA margin is -303.60%, and its revenue ttm is $3.95 Million , which makes it $0.54 revenue per share.

Of the last four earnings reports from Addex Therapeutics Ltd, there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.65 for the next earnings report. Addex Therapeutics Ltd’s next earnings report date is -.

The consensus rating of Wall Street analysts for Addex Therapeutics Ltd is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Addex Therapeutics Ltd stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Addex Therapeutics Ltd has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Addex Therapeutics Ltd has a Buy technical analysis rating based on Technical Indicators (ADX : 19.25, ATR14 : 0.53, CCI20 : 160.98, Chaikin Money Flow : 0.07, MACD : 0.19, Money Flow Index : 76.81, ROC : 5.88, RSI : 57.99, STOCH (14,3) : 68.08, STOCH RSI : 0.51, UO : 56.78, Williams %R : -31.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Addex Therapeutics Ltd in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Addex Therapeutics Ltd

Addex Therapeutics Ltd is a biopharmaceutical company. The company operates through single segment which includes developing drugs to improve human health. It is focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. In addition, it is also engaged in the development of the dipraglurant and ADX71441 program. The company's geographical area of operations includes Switzerland and Europe.

CEO: Tim Dyer

Telephone: +41 228841555

Address: Chemin des Aulx 12, Geneva 1228, , CH

Number of employees: 27

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

100%0%

Bearish Bullish

50%50%

News

Stocktwits